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physiology as well as pathophysiology of vasopressin in 
PKD, the promising effects of tolvaptan treatment, and po-
tential synergistic or additive treatments in combination 
with tolvaptan. In this study, we also review current evi-
dence regarding the effect of influencing disease progres-
sion in PKD by lifestyle changes, especially by fluid intake. 
 © 2017 The Author(s)
Published by S. Karger AG, Basel 
 Introduction 
 In this review, we summarize the current evidence 
about the pathophysiological relation of vasopressin with 
the progression of polycystic kidney disease (PKD), and 
give a comprehensive overview of potential treatment op-
tions, by either blocking the effect of vasopressin using 
the kidney-specific vasopressin V2-receptor antagonist 
(V2RA) tolvaptan or lowering circulating vasopressin 
concentration by changing lifestyle and fluid intake in 
particular. Due to the journal limitation in terms of the 
number of references allowed, we only included papers 
and reviews conducted in the last 10 years.
 Physiological Actions of Vasopressin 
 Arginine vasopressin (AVP) is a hormone pivotal to 
maintain fluid homeostasis in the body, and is secreted af-
ter osmotic as well as hemodynamic stimuli. Vasopressin is 
 Keywords 
 Polycystic kidney disease · Autosomal dominant polycystic 
kidney disease · Vasopressin · Vasopressin V2-receptor · 
Hydration · Cyclic AMP · Aquaporin-2 
 Abstract 
 Vasopressin, also known as arginine vasopressin or antidi-
uretic hormone, plays a pivotal role in maintaining body ho-
meostasis. Increased vasopressin concentrations, measured 
by its surrogate copeptin, have been associated with dis-
ease severity as well as disease progression in polycystic kid-
ney disease (PKD), and in experimental studies vasopressin 
has been shown to directly regulate cyst growth. Blocking 
vasopressin effects on the kidney via the vasopressin V2-re-
ceptor and lower circulating vasopressin concentration are 
potential treatment opportunities that have been the sub-
ject of study in PKD in recent years. Treatment with vaso-
pressin V2-receptor antagonist tolvaptan has been shown 
to inhibit disease progression in experimental studies, as 
well as in a large randomized controlled trial involving 1,445 
patients with autosomal dominant PKD, lowering total kid-
ney volume growth from 5.5 to 2.8%, and the slope of the 
reciprocal of the serum creatinine level from –3.81 to –2.61 
mg per mL –1 /year. Alternatively, lowering circulating vaso-
pressin could delay disease progression. Vasopressin is se-
creted in response to an increased plasma osmolality, which 
in turn is caused by a low fluid or high osmolar intake. Other 
lifestyle factors, like smoking, increase vasopressin concen-
tration. Here, we provide a comprehensive review of the 
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well known for its antidiuretic effects in the kidney; it also 
influences the vascular tonus and is involved in the regula-
tion of the endocrine stress response. There are 3 pathways 
of release for vasopressin. For this review the classical, and 
most well-known, pathway is relevant. Via this pathway, 
vasopressin is released directly into the circulation in re-
sponse to osmotic or hemodynamic stimuli  [1] .
 There are 3 different known receptors for vasopressin 
that are all part of the subgroup rhodopsin – all G-pro-
tein-coupled receptors  [1] . Via the V1a-receptor present 
in many tissues, vasopressin is known to influence he-
patic glycogenolysis, platelet aggregation, and vasocon-
striction during hypovolemia  [1] . The V1b-receptor is 
found in the adenohypophysis, where it influences adre-
nocorticotropic hormone secretion, which stimulates the 
synthesis and secretion of the adrenocortical hormones 
cortisol, androgens, and aldosterone. The V2-receptor is 
mainly located in the collecting ducts and the thick as-
cending limbs of the loops of Henle, and plays a pivotal 
role in body homeostasis because of its antidiuretic effect 
 [1] . Binding of vasopressin to the V2-receptor in the col-
lecting duct increases water permeability and sodium re-
absorption, via the activation of AQP trafficking and the 
epithelial sodium channel, respectively  [2] .
 In 2006, copeptin was introduced as a biomarker for 
measuring circulating vasopressin. At that time there was 
an unmet need to find a biomarker for vasopressin, since 
vasopressin is a small molecule that is unstable in plasma. 
Copeptin has been shown to be a reliable surrogate and 
has been used in many studies in different fields, includ-
ing cardiovascular, renal disease, and PKD  [3] .
 Pathophysiological Effects of Vasopressin in PKD 
 Mutations in either the  PKD1 or  PKD2 gene cause 
 autosomal-dominant PKD (ADPKD), whereas mutations 
in the  PKHD1 gene cause autosomal recessive PKD 
 (ARPKD).  PKHD1 normally encodes the protein fibrocys-
tin, whereas  PKD1 and  PKD2 encode polycystin-1 and 
polycystin-2, respectively  [4] . Both disorders are associated 
with cyst formation in the kidney and are characterized by 
abnormal excessive fluid secretion, as well as excessive pro-
liferation and apoptosis of the tubular epithelial cells  [4] .
 Vasopressin is increased in patients with PKD, and the 
concentration of its surrogate copeptin is associated with 
disease severity when analyzed cross-sectionally  [5] and 
also with disease progression measured longitudinally as 
kidney function decline and kidney growth  [6, 7] . It has 
been shown that vasopressin directly regulates cyst growth 
in rats orthologous to human ARPKD, which phenotypi-
cally resembles human ADPKD. After breeding these rats 
with vasopressin-deficient Brattleboro rats, it was shown 
that rats lacking vasopressin had lower levels of cyclic ad-
enosine monophosphate (cAMP) and that cystogenesis 
was inhibited almost completely. Administration of the 
vasopressin V2-receptor agonist DDAVP recovered the 
full cystic phenotype in these Brattleboro rats  [8] .
 A urine-concentrating defect is thought to be the cause 
of the increased vasopressin concentration in PKD. Find-
ings of a decreased urine concentrating capacity in an ear-
ly phase of ADPKD, before renal impairment occurs, 
strengthen this hypothesis  [9] . When analyzing this urine-
concentrating defect in more detail, Bankir et al. [10] ob-
served that this was a urea-selective concentrating defect; 
patients with PKD had a lower urine/plasma (U/P)–urea 
ratio, whereas no difference in total U/P osmoles or U/P–
sodium ratios compared to healthy controls were ob-
served. This defect is thought to originate in the disrup-
tion of the medullary architecture by cysts, which reduces 
the efficiency of countercurrent exchange of urea.
 Lowering the vasopressin effect on the kidney could 
potentially modify the disease course in ADPKD. This 
either could be accomplished by blocking the effects of 
vasopressin in the kidney using a vasopressin V2RA like 
tolvaptan, or could be accomplished by lowering the cir-
culating vasopressin concentration using lifestyle chang-
es such as increased water intake. Recent preclinical stud-
ies suggest that additional drugs acting downstream from 
the vasopressin V2-receptor could enhance and possibly 
improve the tolerability of vasopressin V2RA and deserve 
further study. Evidence for these approaches is discussed 
in the following sections.
 Tolvaptan as Treatment for PKD 
 The increased vasopressin and cAMP concentration as-
sociated with PKD formed the rationale for exploring the 
effects of vasopressin V2RA. Administration of vasopres-
sin V2RA OPC31260 led to a lowered renal cAMP, inhib-
ited disease development, and either halted progression or 
caused the regression of established disease in animal mod-
els orthologous to the human ARPKD and nephronophthi-
sis (NPH), as well as in mouse models of ADPKD  [11] .
 In the TEMPO 3: 4 Trial, a large randomized con-
trolled study including 1,445 patients with ADPKD, 
tolvaptan slowed the disease progression of ADPKD after 
3 years of treatment by a lower total kidney volume (TKV) 
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tients ( p < 0.001), as well as a decreased slope of the recip-
rocal of the serum creatinine level of –2.61 vs. –3.81 mg 
per mL –1 /year in tolvaptan vs. placebo-treated patients, 
respectively  [12] . Patients were eligible if they had an es-
timated creatinine clearance of  ≥ 60 mL/min. Recent post 
hoc analyses found similar beneficial effects of tolvaptan 
in ADPKD across CKD stages 1–3  [13] , showed that 
tolvaptan use lowered albuminuria  [14] and monocyte 
chemotactic protein-1 excretion  [15] , whereas it in-
creased copeptin concentration  [16] , and significantly 
lowered the incidence of kidney pain events from 16.8 to 
10.1% with a risk reduction of 36%  [17] . A higher albu-
minuria and a higher copeptin concentration at baseline 
both predicted renal function decline in placebo- as well 
as tolvaptan-treated patients, and were both associated 
with a stronger tolvaptan treatment effect  [14, 16] .
 Drugs with Effects That Are Potentially Synergistic or 
Additive to Those of Tolvaptan 
 Tolvaptan has been shown to slow down disease pro-
gression in ADPKD by antagonizing the vasopressin V2-
receptor in the kidney ( Fig. 1 ), lowering intracellular cAMP, 
and inhibiting fluid secretion, and cell proliferation. By in-
terfering with aquaporin-2 (AQP2) trafficking, however, it 
induces aquaresis and enhances vasopressin release. Com-
bining tolvaptan with treatments that lower cAMP or in-
crease AQP2 in the apical membrane of principal cells could 
increase its  efficacy and reduce the aquaretic side-effects 
( Fig. 1 ).
 Long-acting somatostatin analogs acting on soma-
tostatin receptors (SSTR) inhibit adenylyl cyclase and 
slow renal and hepatic cyst expansion in murine and 
small clinical trials of ADPKD. Hopp et al. [18] found an 
additive efficacy of tolvaptan and pasireotide (a SSTR-1, 
-2, -3, and -5 analogue) compared to either treatment 
alone, as well as less aquaresis in the combination therapy 
compared to tolvaptan alone.
 Metformin inhibits complex 1 of the mitochondrial 
 respiratory chain, thus reducing ATP production and 
 increasing AMP  [19] . AMP in turn directly inhibits ade-
nylyl cyclase and activates AMPK. The inhibition of ad-
enylyl cyclase  [20] and activation of phosphodiesterase 
(PDE) 4B by AMPK-mediated phosphorylation are found 
to lower cAMP  [21] . Furthermore, via  AMPK-mediated 
phosphorylation of AQP2 metformin enhances its accu-
mulation in the apical membrane and reduces the aquaret-
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ic effect of tolvaptan  [22] . Currently, 2 phase-2 studies are 
investigating the effect of metformin treatment on disease 
progression in ADPKD (Clinicaltrial.gov Identifiers: 
NCT02656017 and NCT02903511).
 Statins and tetracycline antibiotics demeclocycline 
and doxycycline, may also have synergistic effects with 
tolvaptan. Statins may lower cAMP through the down-
regulation of Gα s protein  [23] and induce membrane ac-
cumulation of AQP2 via the inhibition of endocytosis 
 [24] , thus reducing aquaresis. Demeclocycline decreases 
adenylate cyclase 5/6 expression and, consequently, 
cAMP generation  [25] . In animal studies, doxycycline 
significantly decreased renal tubule cell proliferation and 
inhibited cystic disease progression in a rat model orthol-
ogous to human ARPKD  [26] . However, the nephrotox-
icity of these drugs when used at high doses may limit 
their potential for the treatment of PKD; for example, 
doxycycline at a high dose was found to aggravate cyst 
growth and fibrosis in a mouse model of type 3 NPH  [27] .
 Water Intake 
 Lowering vasopressin concentration and slowing 
down disease progression in PKD by increasing water in-
take has been a topic of studies for many years. It should 
be noted that the effects of vasopressin V2RA and en-
hanced hydration are not identical ( Table 1 ). Promising 
effects of increased water intake have been found by 
Nagao et al. [28] , who found in rats orthologous to hu-
man ARPKD, that high water intake decreased urinary 
vasopressin excretion by 68.3%, and the renal expression 
of vasopressin V2-receptors was decreased. High water 
intake slowed the disease progression in both male and 
female rats, decreased kidney–body weight ratio to 29.8 
and 27.0%, respectively, and reduced the serum urea ni-
trogen in the male rats from 38.7 to 26.3 mg/dL. Similar 
results were obtained by Hopp et al. [29] in the same rat 
model, but not in a  Pkd1- mouse model. In these rats, a 
4-fold increase in urine output led to reductions in urine 
vasopressin and renal levels of cAMP, with a marked pro-
tective effect on the development of PKD, as reflected by 
lower kidney weights, plasma urea, and cystic and fibrot-
ic indexes  [29] .
 When studying the effects of increased water intake in 
human ADPKD, the beneficial effects on disease progres-
sion have not yet been confirmed. In a pilot clinical study 
by Barash et al. [30] , 13 ADPKD patients were instructed 
to increase their water intake for 7 days, resulting in aver-
age intake of 3.1 L/day. This caused a significant urine 
osmolality decline of 46% to 270 mOsm/L ( p = 0.04), low-
ering it below plasma osmolality, and thus likely causing 
a decreased vasopressin concentration (not measured). 
Higashihara et al. [31] performed a study in 34 patients 
with ADPKD who received either a high or free water in-
take during 1 year, leading to mean 24-h urine volumes 
of 2.6 vs. 1.4 L per day ( p < 0.001). Plasma AVP and co-
peptin were, as expected, lower in the high water intake 
group (both  p = 0.02). However, non-significant trends 
toward faster estimated glomerular filtration rate (eGFR) 
decline (–5.6 mL/min/1.73 m 2 vs. –1.1,  p = 0.06) and TKV 
growth (9.68%/year vs. 5.28,  p = 0.08), rather than a ben-
Table 1.  Different effects of V2R antagonists and enhanced hydration (Bankir et al. [2])
Outcome Increased fluid intake V2R antagonists
 Patient behavior Voluntary frequent drinking Taking a pill
Adherence to treatmen t Poor (difficult to drink without thirst) Good (easy)
Plasma osmolality Decreased Increased
Vasopressin secretion and plasma level Decreased Increased
Vasopressin effects mediated by other 
receptors (V1aR and V1bR)*
Reduced Enhanced
Possible side effects Aversion to water, frequent need to 
urinate, risk of hyponatraemia
Thirst, frequent need to 
urinate, risk of dehydration
Financial costs None High
 V1aR, vasopressin V1a receptor; V1bR, vasopressin V1b receptor.
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eficial effect, were observed in the high water intake group 
compared to the free water intake group. Finding no ben-
eficial effects of an increased water intake in this study 
might have been due to shortcomings of the study design. 
First, the study had only 34 participants, potentially lead-
ing to an underpowered statistical analysis. Second, for 
assessment of the primary end point, historical data were 
used. Third, participants were not randomized but could 
enroll in the group they preferred, potentially leading to 
a selection bias, as is reflected by a significantly higher 
24-h urine volume in the high water intake group at base-
line. Finally, the high water intake group was instructed 
to drink  ∼ 50 mL water/kg body weight/day (2.5–3.0 L of 
water/day) or more, preferably during the first half of the 
day, which might not be enough to change the disease 
course and show a beneficial effect.
 These inconclusive results suggest a need for future 
randomized controlled trials that study the effect of an 
increased fluid intake on disease progression in CKD and 
PKD in particular. Currently, there is an ongoing trial 
studying the effect of increased fluid intake of 1–1.5 L/day 
in CKD (Clinicaltrial.gov Identifier: NCT01766687), and 
another clinical trial in 180 ADPKD patients, of which 
half will have prescribed fluid intake to reduce urine 
 osmolality to  ≤ 270 mOsm/kg  [32] .
 Dietary Factors 
 Besides water intake, other lifestyle factors might influ-
ence the disease course of PKD by lowering the vasopressin 
concentration ( Table  2 ). The recommendations in the 
KHA-CARI ADPKD guideline for diet and lifestyle man-
agement are based on lifestyle modifications that have 
proven to be effective in the management of early CKD pro-
gression, as there is no evidence specific to ADPKD that 
would alter these recommendations. It includes a moderate 
protein diet (0.75–1.0 g/kg/day), a restricted dietary sodium 
intake of 100 mmol/day (i.e., 2.3 g sodium or 6 g salt) or less, 
to drink fluid to satisfy thirst, and to stop smoking  [33] .
 In a large general population cohort, we previously 
found that a higher copeptin concentration was cross-sec-
tionally associated with lower water intake (measured as 
24-h urine volume), higher 24-h sodium and urea excre-
tion (in steady state markers of sodium and protein in-
take), a lower 24-h potassium excretion, higher number of 
cigarettes smoked, as well as alcohol use and higher num-
ber of alcoholic consumptions  [34] . Nonlinear relations 
between copeptin concentration and body mass index, as 
well as plasma glucose concentration, were observed.
 In the CRISP study involving 241 patients with  ADPKD, 
high urine osmolality (a marker for AVP activity), high 
urine sodium excretion (a marker for sodium intake), and 
low serum HDL-cholesterol were associated with the rates 
of TKV increase and eGFR decline  [35] . In a recent post 
hoc analysis of the HALT-PKD clinical trials, dietary so-
dium – measured as averaged sodium excretion – showed 
to be associated with the rate of TKV increase but not with 
the rate of eGFR decline in ADPKD patients with an eGFR 
over 60 mL/min/1.73 m 2 . In patients with an eGFR 25–60 
mL/min/1.73 m 2 averaged sodium excretion was associ-
ated with reaching a composite end point of 50% reduc-
tion of eGFR, end-stage renal disease (ESRD) or death, 
and with a faster rate of eGFR decline  [36] . Markers of 
vasopressin were not studied in the HALT-PKD trials.
 Protein intake, both a single meal and chronic high 
intake, is known to directly increase the circulating vaso-
pressin concentration and simultaneously GFR. It chang-
es the urea handling by the renal tubule, as the fractional 
excretion of urea is increased following a protein meal, 
and is thought to participate in glomerular hyperfiltra-
tion and kidney hypertrophy  [37] . As reviewed in the 
KHA-CARI guideline, the only study investigating pro-
tein intake in ADPKD was a secondary analysis of the 
MDRD Study analyzing 200 patients with ADPKD, where 
they found no clear benefit of low protein intake and de-
cline in GFR. Meta-analyses in chronic kidney disease in-
dicate either no effect or a modest benefit of protein-re-
stricted diets  [33] .
 Recently, a very promising pilot study treated 34  ADPKD 
patients with a low osmolar, water-adjusted diet and ob-
served a lower copeptin concentration on this dietary re-
gime. Patients received a low sodium (1,500 mg/day), low 
protein (daily protein dietary allowance, 0.8 g/kg body 
weight), and low urea (i.e., avoidance of preservatives, food 
additives, bulking agents, and chewing gum) diet, com-
bined with individually adjusted water intake, to ensure 
urine osmolality of 280 mOsm/kg or lower. After 2 weeks 
of treatment, patients had significantly lower plasma co-
peptin levels compared to non-treated patients (6.2 ± 3.05 
vs. 5.3 ± 2.5 pmol/L respectively;  p = 0.02). Total urinary 
solute decreased only in the intervention group and sig-
nificantly differed between groups at week 1 ( p = 0.03)  [38] .
 Other (Lifestyle) Factors 
 Hypothetically, caffeine has a specific deleterious ef-
fect in PKD via PDE inhibition, but when analyzing the 
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Table 2.  Studies that suggest an association between lifestyle factors and polycystic kidney disease progression
Study Model Lifestyle Study type Outcome measure(s) Main findings
Nagao 






Water intake Interventional 
animal study
Urinary AVP 




Urinary AVP excretion decreased by 68.3%, AVP V2 
receptor expression normalized under high water 
intake, kidney-to-body-weight decreased 29.8 and 
27.0% in male and female rats, respectively, and SUN 
decreased from 38.7 to 26.3 mg/dL in the male rats
Hopp 







Water intake Interventional 
animal study
Urine output, plasma 
AVP, renal cAMP, 
kidney weight, cyst 
and fibrosis, plasma 
urea and creatinine
Urine output was increased by fourfold and all studied 
parameters were lower in rats on a high water intake. 
Despite a more than sevenfold increased urine output 
in Pkd1-mice, no significant differences on any of the 
markers were observed
Barash 









24-H urine volume increased 64% (to 3.1 L), urine 
osmolality decreased 46% (to 270±21 mOsm/L)
Higashihara 










Plasma AVP and copeptin lower in high (HW) vs. low 
water (LW) intake (both p = 0.02), whereas no effect on 
eGFR decline (mL/min/1.73 m2), being –5.6 HW vs. –1.1 
LW (p = 0.06) or TKV growth (9.68 HW vs. 5.28 LW; 
p = 0.08) were observed
Torres 














Urine osmolality (as marker for AVP activity), urine 
sodium excretion, and low serum HDL-cholesterol were 
associated with TKV and eGFR slopes. Also baseline 
BSA, BMI, and estimated protein intake were associated 
with TKV increase over time
Torres 









TKV growth, eGFR 
change and risk to 
reach composite 
endpoints
Urine sodium excretion was significantly associated with 
TKV growth (p < 0.001), and a non-significant trend for 
eGFR decline (p = 0.09). Average urine sodium excretion 
was significantly associated with eGFR decline (p < 0.001) 
with risk to reach the composite end point of 50% 
reduction in eGFR, ESRD, or death
Amro 










Plasma copeptin, urine 
osmolality, and total 
urinary solute
Mean plasma copeptin levels and urine osmolality 
declined from 6.2±3.05 to 5.3±2.5 pmol/L (p = 0.02) and 
from 426±193 to 258±117 mOsm/kg water (p = 0.01), 
respectively, in the intervention group. Total urinary 
solute decreased only in the intervention group and 
significantly differed between groups at week 1 (p = 0.03)
Vendramini 








Mean caffeine intake was significantly lower in ADPKD 
patients versus controls (86 vs. 134 mg/day). 
No significant differences were observed for tertiles of 
coffee intake and eGFR, TKV, or hypertension
Ozkok 














Rapidly progressing patients had significantly higher 
history of smoking (36 vs. 18%, p = 0.01) and pack-years 
of smoking. A Cox regression did not confirm that 
smoking predicted progression of CKD in ADPKD 
patients (p = 0.63), whereas age, the presence of hepatic 
cysts, hypertension, and proteinuria did (p = 0.01, 
p = 0.001, p = 0.04 and p = 0.02, respectively)






Progression to ESRD In smoking men (average pack-years 16.9±20.2), a 
significant dose-dependent increase of the risk to 
progress to ESRD compared to controls (average 
pack years 8.2±14.9) was found (p = 0.001)
Veloso Sousa 






SUN, cystic index, 
renal fibrosis and cell 
proliferation
In Pkd1-mice, smoking increased SUN (57.2±32.4 vs. 
35.7±6.0 mg/dL, p < 0.05), the cystic index (17.4 vs. 4.6%; 
p < 0.05), renal fibrosis (1.1 vs. 0.3%; p < 0.0001) and cell 
proliferation in cystic epithelia (2.1 vs. 1.1%; p < 0.05)
 ARPKD, autosomal recessive polycystic kidney disease; AVP, arginine vasopressin; SUN, serum urea nitrogen; cAMP, cyclic adenosine monophosphate; 
ADPKD, autosomal dominant polycystic kidney disease; eGFR, estimated glomerular filtration rate; TKV, total kidney volume; HDL, high-density lipopro-
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ADPKD patients, no associations were found between 
coffee intake and eGFR or TKV  [39] . However, a major-
ity of these patients (63%) had previously been advised to 
lower coffee consumption, and the mean coffee intake 
was significantly lower compared to healthy controls 
(86 ± 77 vs. 134 ± 116 mg/day,  p  ≤ 0.001)  [39] .
 Nicotine is known to have an antidiuretic effect and 
causes an increased vasopressin concentration. A history 
of smoking and pack-year of cigarettes smoked, were sig-
nificantly associated with rapid disease progression in 
ADPKD  [40] . In ADPKD patients, smoking also corre-
lated with proteinuria and an increased risk of progres-
sion to ESRD  [41] . A recent mouse study in  Pkd1 -mice 
revealed that smoking aggravated the renal phenotype of 
these mice, thereby supporting the theoretical accelerat-
ing effect of smoking on PKD-progression  [42] .
 Vasopressin was associated with obesity, metabolic 
syndrome, and diabetes mellitus in the Malmö Diet and 
Cancer Study cardiovascular cohort ( n = 2,064)  [43] . In a 
separate, small case–control study in subjects with pre-
served renal function, the presence of ADPKD was asso-
ciated with components of metabolic syndrome such as 
hypertension, abdominal obesity, and higher fasting gly-
cemia  [44] . Markers of vasopressin concentration were 
not studied.
 Conclusions 
 It is important that future studies focus on the rela-
tionship between increased fluid consumption and low-
ering osmolar intake on vasopressin concentration, and 
most importantly, the progression of PKD. If future re-
search determines that reducing vasopressin concentra-
tion leads to slowed disease progression, other lifestyle 
factors, like smoking and obesity, could be studied be-
cause they are associated with increased vasopressin con-
centrations.
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